Last reviewed · How we verify
Deanxit
At a glance
| Generic name | Deanxit |
|---|---|
| Also known as | Flupentixol and Melitracen, Deanxit as anti-anxiety treatment |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessment of SSD in Outpatients Using SSS-CN
- Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (NA)
- Bioequivalence Study to Compare Two Formulations of Deanxit® (PHASE1)
- The Role of Neuromodulators in Refractory Functional Dyspepsia (NA)
- Hierarchical Treatment Based on Somatization Symptom Checklist (PHASE1, PHASE2)
- Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors (PHASE3)
- Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia (PHASE4)
- Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deanxit CI brief — competitive landscape report
- Deanxit updates RSS · CI watch RSS
- RenJi Hospital portfolio CI